Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiota transplantation added to tislelizumab plus TKI for advanced hepatocellular carcinoma with secondary drug resistance
ChiCTR2200058471Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and allogeneic fecal microbiota in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease control rate. Started Aug 2022; status: completed.
02
Drugs
tislelizumaballogeneic fecal microbiota
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200058471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058471.